Unknown

Screen Addiction and Postoperative Pain

Time for a Diagnostic Paradigm Shift From STEMI/NSTEMI to OMI/NOMI

Interferential Current and Transcutaneous Electrical Nerve Stimulation for Pain After Cesarean Section

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Effects of Three Different Methods Applied to Patients After Spine Surgery on Nausea, Thirst and Comfort

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Robot-Assisted Intensive Physiotherapy in Individuals With Spinal Cord Injury

Comparison of Two Expansion Techniques for Horizontal Bone Deficiency

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Kinesiotaping in Isolated Meniscus Injuries

Effects of Chocolates With Different Cocoa Content on Postprandial Blood Glucose in Healthy Adults

THE EFFECT OF CRP/LYMPHOCYTE AND NEUTROPHIL/LYMPHOCYTE RATIOS ON LENGTH OF HOSPITAL STAY AND MORTALITY IN PATIENTS ADMITTED TO THE BURN UNIT

Effects of Plantar Vibration on Gait and Balance in Stroke

Turkish Version of the BARSE

Biomarkers, Abdominal Muscle, and Frailty in CKD

Stress Management Intervention for Young Turkish Women

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)